Eton Pharmaceuticals, Inc. (Nasdaq:ETON) announced on Friday that it has acquired Galzin (zinc acetate), an FDA-approved maintenance treatment for patients with Wilson Disease initially treated with a chelating agent.

Wilson Disease affects fewer than 5,000 patients in the United States. Eton plans to begin US commercialization in Q1 2025, leveraging its metabolic sales force to support healthcare providers treating this rare condition.

Eton will offer Galzin through its Eton Cares patient support program, featuring a USD0 co-pay for qualified commercial patients, insurance benefits investigation, educational resources and prescription fulfilment. European rights to the product, commercialized as Wilzin by a third party, are also part of the acquisition. Under an existing agreement, Eton will continue supplying the product while the third party handles European commercialization.

Stifel acted as the exclusive financial advisor to Eton for this transaction.